Author of

• 35188

  +

  P21 - Locoregional and Oligometastatic Disease - Treatment of Locally Advanced NSCLC (ID 131)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Locoregional and Oligometastatic Disease
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 35210

    +

    P21.16 - Do Patients who Underwent Lung Resection for Non-Small Cell Lung Cancer and Skip-N2 Metastases Show Better Survival? (ID 2374)

    00:00 - 00:00  |  Presenting Author(s): Alejandra Libreros
    • Abstract
    • Slides

    Introduction
    

    
    Non-small cell lung cancer (NSCLC) with ipsilateral mediastinal involvement (N2) without N1 involvement is known as skip metastasis (pN0N2).

    A large number of studies suggest that this heterogeneous subgroup of patients with N2 disease shows better survival. The aim of this study to evaluate and compare the survival of patients with skip metastasis and patients with pN1N2 involvement.

    Methods
    

    Retrospective study of patients with NSCLC who underwent lung resection and lymphadenectomy with pN2.

    Patients were divided into two groups. Non skip Group: with involvement of N1 (pN1N2). Skip Group: without involvement of N1 (pN0N2).

    Demographic data, smoking, tumor location, tumor size, histology, vascular and pleural invasion, type of surgery, length of stay and survival (S), were studied and were subjected to a univariate and multivariate analysis.

    Results
    

    Between January 2011 and June 2019, 83 patients with NSCLC were operated with a result of pN2.

    64 (77%) patients were men; 19 (23%) were women. The mean age was 66 ± 10 years.

    Non Skip group = 54 patients (65%) and Skip Group = 29 patients (35%).

    Active smokers: 25 (30%), ex-smokers: 48 (58%), non-smokers: 9 (11%), unknown: 1 (1%).

    Tumor location: Left upper lobe: 27 (32.5%), right upper lobe: 26 (31.3%), right lower lobe: 13 (15.7%), left lower lobe: 12 (14.5%), right middle lobe: 5 (6%).

    Size: <3cm: 33 patients (39.8%), 3cm-5cm: 30 patients (36.1%) and> 5cm: 20 patients (24.1%).

    Histology: Adenocarcinoma: 48 (58%), squamous cell carcinoma: 27 (33%), neuroendocrine: 3 (3.6%), others: 3 (3.6%), large cells: 1 (1.2%) and mixed: 1 (1.2%).

    Lobectomy was performed in 63 (76%) patients, pneumonectomy in 12 (15,5%), wedge resection in 4 (4,8%) and anatomical segmentectomy 2 (2,4%).

    Lenght of stay: Non-skip group: 7 days +/- 3 and skip group: 8 days +/- 5. p = 0.92.

    Female gender is associated with skip metastases with statistical significance in univariate and multivariate analysis (p = 0.003; p = 0.017 respectively).

    The median S was 43 months in the non-skip group versus (vs) 50 months in the skip group.

    The S at one year was: 51% in the non-skip group vs. 70% in the skip group.

    The S at 3 years was: 36% in the non-skip group vs. 54% in the skip group.

    The S at 5 years was: 36% in the non-skip group vs. 44% in the skip group. p = 0.23.

    Three-year survival analysis of the subgroup of N2 single station did not show significant differences in the group no skip vs skip. (30% vs. 50% respectively). (p = 0.47)

    Conclusion
    

    In this study, female gender is a variable associated with the presence of Skip metastasis.

    Skip group showed a better survival vs. non-skip although these results were not statistically significant.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.